Table 3.

Results of univariate analysis for prognosis evaluated by the Kaplan-Meier method

FactorsOS
EFS
5 yP*5 yP*
Age (y)
    59 or younger (n = 63)0.91<0.0010.85<0.001
    60 or older (n = 75)0.620.51
Sex
    Male (n = 83)0.710.1290.630.237
    Female (n = 55)0.840.75
Histology
    DLBCL + MALT (n = 55)0.850.3510.690.924
    DLBCL (n = 83)0.690.67
Macroscopic type
    Mass forming (n = 85)0.710.3860.690.795
    Others (n = 37)0.820.68
Depth of tumor invasion
    Mucosa∼MP (n = 63)0.840.0490.730.440
    Serosa (n = 67)0.650.61
Clinical stage
    I (n = 73)0.860.0040.770.015
    II1 or more (n = 64)0.640.58
Chemotherapy
    Yes (n = 65)0.770.6940.680.797
    No (n = 73)0.750.67
BCL6-involved translocation
    Positive (n = 16)0.870.7250.730.898
    Negative (n = 64)0.780.66
c-MYC–involved translocation
    Positive (n = 7)1.000.3190.830.495
    Negative (n = 64)0.780.65
FOXP1-involved translocation
    Positive (n = 4)0.670.8490.670.564
    Negative (n = 91)0.780.66
IGH-involved translocation
    Positive (n = 35)0.900.0070.800.025
    Negative (n = 74)0.730.62
Extra copies of MALT1/BCL2
    Positive (n = 24)0.770.9010.670.870
    Negative (n = 78)0.750.65
Extra copies of FOXP1/BCL6
    Positive (n = 18)0.740.6410.660.527
    Negative (n = 79)0.790.67
Extra copies of c-MYC
    Positive (n = 7)0.860.7910.860.406
    Negative (n = 64)0.790.65
CD10 expression
    Positive (n = 55)0.770.7630.700.912
    Negative (n = 83)0.750.66
BCL6 expression
    Positive (n = 72)0.820.2100.690.714
    Negative (n = 66)0.700.66
MUM1 expression
    Positive (n = 80)0.700.4730.610.399
    Negative (n = 58)0.840.78
Immunophenotype by Hans
    GCB (n = 71)0.790.9660.700.893
    Non-GCB (n = 67)0.720.66
FOXP1 expression
    Positive (n = 31)0.730.3010.580.134
    Negative (n = 51)0.750.71
  • * Log-rank test.